
Claims of alleged wrongdoing have no hold in reality, says Dicerna in a filing sent to the US Securities and Exchange Commission.
This stance has been taken by Dicerna after some shareholders have filed suits against the firm, alleging violations of the US Securities Exchange Act.
"The company, parent and purchaser believe the claims asserted in each of the complaints are without merit," the document reads.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.